Journal of the American Chemical Society
Communication
2012, 134, 6120−6123. (i) Fowler, B. S.; Laemmerhold, K. M.; Miller,
S. J. J. Am. Chem. Soc. 2012, 134, 9755−9761. (j) Voica, A.-F.;
Mendoza, A.; Gutekunst, W. R.; Fraga, J. O.; Baran, P. S. Nat. Chem.
2012, 4, 629−635.
(2) For examples of late-stage fluorination, see: (a) Watson, D. A.;
Su, M.; Teverovskiy, G.; Zhang, Y.; Garcia-Fortanet, J.; Kinzel, T.;
Buchwald, S. L. Science 2009, 325, 1661−1664. (b) Tang, P.; Furuya,
T.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 12150−12154. For selected
examples of di- and trifluoromethylation, see: (c) Ji, Y.; Brueckl, T.;
Baxter, R. D.; Fujiwara, Y.; Seiple, I. B.; Su, S.; Blackmond, D. G.;
Baran, P. S. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 14411−14415.
(d) Nagib, D. A.; MacMillan, D. W. C. Nature 2011, 480, 224−228.
(e) Fujiwara, Y.; Dixon, J. A.; Rodriguez, R. A.; Baxter, R. D.; Dixon,
D. D.; Collins, M. R.; Blackmond, D. G.; Baran, P. S. J. Am. Chem. Soc.
2012, 134, 1494−1497. (f) Fujiwara, Y.; Dixon, J. A.; O’Hara, F.;
Funder, E. D.; Dixon, D. D.; Rodriguez, R. A.; Baxter, R. D.; Herle, B.;
Sach, N.; Collins, M. R.; Ishihara, Y.; Baran, P. S. Nature 2012, 492,
95−99.
(3) (a) Furuya, T.; Kuttruff, C. A.; Ritter, T. Curr. Opin. Drug
Discovery Dev. 2008, 11, 803−819. (b) Bohm, H.-J.; Banner, D.;
̈
Bendels, S.; Kansy, M.; Kuhn, B.; Muller, K.; Obst-Sander, U.; Stahl,
̈
M. ChemBioChem 2004, 5, 637−643. (c) Muller, K.; Faeh, C.;
̈
Diederich, F. Science 2007, 317, 1881−1886. (d) Purser, S.; Moore, P.
R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320−330.
(e) Furuya, T.; Kamlet, A. S.; Ritter, T. Nature 2011, 473, 470−477.
(4) For reviews of deoxyfluorination, see: (a) Singh, R. P.; Shreeve, J.
M. Synthesis 2002, 2561−2578. (b) Singh, R. P.; Meshri, D. T.;
Shreeve, J. M. Adv. Org. Synth. 2006, 2, 291−326. (c) Kirk, K. L. Org.
Process Res. Dev. 2008, 12, 305−321. (d) Al-Maharik, N.; O’Hagan, D.
Aldrichimica Acta 2011, 44, 65−75.
(5) For DAST, see: (a) Middleton, W. J. J. Org. Chem. 1975, 40,
574−578. For Deoxo-fluor, see: (b) Lal, G. S.; Pez, G. P.; Pesaresi, R.
J.; Prozonic, F. M.; Cheng, H. J. Org. Chem. 1999, 64, 7048−7054. For
DFI, see: (c) Hayashi, H.; Sonoda, H.; Fukumura, K.; Nagata, T.
Chem. Commun. 2002, 1618−1619. For Xtal-fluor, see: (d) Beaulieu,
F.; Beauregard, L.-P.; Courchesne, G.; Couturier, M.; LaFlamme, F.;
L’Heureux, A. Org. Lett. 2009, 11, 5050−5053. For Fluolead, see:
(e) Umemoto, T.; Singh, R. P.; Xu, Y.; Saito, N. J. Am. Chem. Soc.
2010, 132, 18199−18205. For other deoxyfluorinating reagents, see:
(f) Yarovenko, N. N.; Raksha, M. A.; Shemanina, V. N.; Vasil’eva, A. S.
Zh. Obshch. Khim. 1957, 27, 2246−2250. (g) Takaoka, A.; Iwakiri, H.;
Ishikawa, N. Bull. Chem. Soc. Jpn. 1979, 52, 3377−3380.
(h) Munyemana, F.; Frisque-Hesbain, A.-M.; Devos, A.; Ghosez, L.
Tetrahedron Lett. 1989, 30, 3077−3080.
(6) Modern Fluoroorganic Chemistry; Kirsch, P., Ed.; Wiley-VCH:
Weinheim, Germany, 2004.
(7) Tang, P.; Wang, W.; Ritter, T. J. Am. Chem. Soc. 2011, 133,
11482−11484.
(8) For example, storage recommendations for everolimus are a
temperature of −20 °C, exclusion of light, and the presence of BHT as
a stabilizer, See: European Medicines Agency. Evaluation of Medicines
for Human Use, London, 29 May 2009, Doc. Ref.: EMEA/533232/
(9) (a) Lee, E.; Kamlet, A. S.; Powers, D. C.; Neumann, C. N.;
Boursalian, G. B.; Furuya, T.; Choi, D. C.; Hooker, J. M.; Ritter, T.
Science 2011, 334, 639−642. (b) Lee, E.; Hooker, J. M.; Ritter, T. J.
Am. Chem. Soc. 2012, 134, 17456−17458.
2473
dx.doi.org/10.1021/ja3125405 | J. Am. Chem. Soc. 2013, 135, 2470−2473